ARIAD Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ARIAD Pharmaceuticals, Inc.
AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.